Press releases
Genomics Announces New Extension and Expansion of Drug Discovery Collaboration with Vertex
17 Jul 2024
The three-year extension expands the range of therapeutic areas and genomic data insights and also explores the use of genomic risk to better define patient subgroups
Genomics and GSK establish precision medicine collaboration to assess polygenic risk scores in clinical trial design
30 Apr 2024
The collaboration, across multiple therapeutic areas, will evaluate how polygenic risk scores could be used to improve clinical trial design and efficiency
Genomics and MassMutual's program enables understanding health risks through genetic testing
9 Apr 2024
The wellness offering utilizes advanced genetics to provide personalized risk information for common and preventable diseases, including heart disease, diabetes, breast and prostate cancer
Genomics plc selected as one of Bloomberg’s 25 UK Startups to Watch
24 Oct 2023
Genomics plc has been selected from among more than 1,500 applications to be included in Bloomberg’s inaugural 25 UK Startups to Watch list. Bloomberg canvassed the UK to find 25 startups that represent the diversity and innovation of the country's startup scene. The Editors wanted to hear about companies that are growing fast, working on something truly unique and come from a diverse group of founders from all over the UK. Genomics plc co-Founder, Professor Sir Peter Donnelly, was also one of three founders from companies in the list to be on stage at the Bloomberg Technology Summit to discuss the Genomics plc story and the wider life sciences/tech sector.
Genomics plc bolsters executive leadership team with two new hires
25 Nov 2022
Genomics plc has today announced that Mark Toms and Nick DeFilippo have joined its leadership team as Chief Medical Officer and Chief Commercial Officer, respectively. Both join the company’s executive leadership team.
Genomics plc announces genetic risk scoring partnership with Our Future Health to test new personalised disease prevention approaches
10 Oct 2022
Genomics plc have today announced a partnership with Our Future Health to generate polygenic risk scores (PRS) as part of the research programme’s aim to find new ways to prevent, detect and treat common diseases such as dementia, diabetes, heart disease, stroke, and cancer.
Genomics plc announces extension of drug discovery collaboration with Vertex
3 Nov 2021
Companies confirm a two-year extension of their collaboration using genomics and machine learning to identify novel targets for innovative medicines and accelerate drug discovery
Genomics plc announces publication of article showing improved risk prediction for cardiovascular disease across ethnicities
6 Apr 2021
• Polygenic risk scores (PRS) substantially enhance risk prediction in cardiovascular disease (CVD), the #1 cause of death around the world
• These study results represent the first clinical validation of such a tool across multiple ancestries and ethnicities
Genomics plc’s integrated risk tool substantially improves coronary artery disease prediction
3 Mar 2021
• Genomics plc’s method outperforms current tools and could help save more than 2,000 lives annually in the US alone
• Opportunity to identify individuals who are at risk of heart disease and target immediate prevention
Press releases
Genomics Announces New Extension and Expansion of Drug Discovery Collaboration with Vertex
17 Jul 2024
The three-year extension expands the range of therapeutic areas and genomic data insights and also explores the use of genomic risk to better define patient subgroups
Genomics and GSK establish precision medicine collaboration to assess polygenic risk scores in clinical trial design
30 Apr 2024
The collaboration, across multiple therapeutic areas, will evaluate how polygenic risk scores could be used to improve clinical trial design and efficiency
Genomics and MassMutual's program enables understanding health risks through genetic testing
9 Apr 2024
The wellness offering utilizes advanced genetics to provide personalized risk information for common and preventable diseases, including heart disease, diabetes, breast and prostate cancer
Genomics plc selected as one of Bloomberg’s 25 UK Startups to Watch
24 Oct 2023
Genomics plc has been selected from among more than 1,500 applications to be included in Bloomberg’s inaugural 25 UK Startups to Watch list. Bloomberg canvassed the UK to find 25 startups that represent the diversity and innovation of the country's startup scene. The Editors wanted to hear about companies that are growing fast, working on something truly unique and come from a diverse group of founders from all over the UK. Genomics plc co-Founder, Professor Sir Peter Donnelly, was also one of three founders from companies in the list to be on stage at the Bloomberg Technology Summit to discuss the Genomics plc story and the wider life sciences/tech sector.
Genomics plc bolsters executive leadership team with two new hires
25 Nov 2022
Genomics plc has today announced that Mark Toms and Nick DeFilippo have joined its leadership team as Chief Medical Officer and Chief Commercial Officer, respectively. Both join the company’s executive leadership team.
Genomics plc announces genetic risk scoring partnership with Our Future Health to test new personalised disease prevention approaches
10 Oct 2022
Genomics plc have today announced a partnership with Our Future Health to generate polygenic risk scores (PRS) as part of the research programme’s aim to find new ways to prevent, detect and treat common diseases such as dementia, diabetes, heart disease, stroke, and cancer.
Genomics plc announces extension of drug discovery collaboration with Vertex
3 Nov 2021
Companies confirm a two-year extension of their collaboration using genomics and machine learning to identify novel targets for innovative medicines and accelerate drug discovery
Genomics plc announces publication of article showing improved risk prediction for cardiovascular disease across ethnicities
6 Apr 2021
• Polygenic risk scores (PRS) substantially enhance risk prediction in cardiovascular disease (CVD), the #1 cause of death around the world
• These study results represent the first clinical validation of such a tool across multiple ancestries and ethnicities
Genomics plc’s integrated risk tool substantially improves coronary artery disease prediction
3 Mar 2021
• Genomics plc’s method outperforms current tools and could help save more than 2,000 lives annually in the US alone
• Opportunity to identify individuals who are at risk of heart disease and target immediate prevention
Press releases
Genomics Announces New Extension and Expansion of Drug Discovery Collaboration with Vertex
17 Jul 2024
The three-year extension expands the range of therapeutic areas and genomic data insights and also explores the use of genomic risk to better define patient subgroups
Genomics and GSK establish precision medicine collaboration to assess polygenic risk scores in clinical trial design
30 Apr 2024
The collaboration, across multiple therapeutic areas, will evaluate how polygenic risk scores could be used to improve clinical trial design and efficiency
Genomics and MassMutual's program enables understanding health risks through genetic testing
9 Apr 2024
The wellness offering utilizes advanced genetics to provide personalized risk information for common and preventable diseases, including heart disease, diabetes, breast and prostate cancer
Genomics plc selected as one of Bloomberg’s 25 UK Startups to Watch
24 Oct 2023
Genomics plc has been selected from among more than 1,500 applications to be included in Bloomberg’s inaugural 25 UK Startups to Watch list. Bloomberg canvassed the UK to find 25 startups that represent the diversity and innovation of the country's startup scene. The Editors wanted to hear about companies that are growing fast, working on something truly unique and come from a diverse group of founders from all over the UK. Genomics plc co-Founder, Professor Sir Peter Donnelly, was also one of three founders from companies in the list to be on stage at the Bloomberg Technology Summit to discuss the Genomics plc story and the wider life sciences/tech sector.
Genomics plc bolsters executive leadership team with two new hires
25 Nov 2022
Genomics plc has today announced that Mark Toms and Nick DeFilippo have joined its leadership team as Chief Medical Officer and Chief Commercial Officer, respectively. Both join the company’s executive leadership team.
Genomics plc announces genetic risk scoring partnership with Our Future Health to test new personalised disease prevention approaches
10 Oct 2022
Genomics plc have today announced a partnership with Our Future Health to generate polygenic risk scores (PRS) as part of the research programme’s aim to find new ways to prevent, detect and treat common diseases such as dementia, diabetes, heart disease, stroke, and cancer.
Genomics plc announces extension of drug discovery collaboration with Vertex
3 Nov 2021
Companies confirm a two-year extension of their collaboration using genomics and machine learning to identify novel targets for innovative medicines and accelerate drug discovery
Genomics plc announces publication of article showing improved risk prediction for cardiovascular disease across ethnicities
6 Apr 2021
• Polygenic risk scores (PRS) substantially enhance risk prediction in cardiovascular disease (CVD), the #1 cause of death around the world
• These study results represent the first clinical validation of such a tool across multiple ancestries and ethnicities
Genomics plc’s integrated risk tool substantially improves coronary artery disease prediction
3 Mar 2021
• Genomics plc’s method outperforms current tools and could help save more than 2,000 lives annually in the US alone
• Opportunity to identify individuals who are at risk of heart disease and target immediate prevention
Press releases
Genomics Announces New Extension and Expansion of Drug Discovery Collaboration with Vertex
17 Jul 2024
The three-year extension expands the range of therapeutic areas and genomic data insights and also explores the use of genomic risk to better define patient subgroups
Genomics and GSK establish precision medicine collaboration to assess polygenic risk scores in clinical trial design
30 Apr 2024
The collaboration, across multiple therapeutic areas, will evaluate how polygenic risk scores could be used to improve clinical trial design and efficiency
Genomics and MassMutual's program enables understanding health risks through genetic testing
9 Apr 2024
The wellness offering utilizes advanced genetics to provide personalized risk information for common and preventable diseases, including heart disease, diabetes, breast and prostate cancer
Genomics plc selected as one of Bloomberg’s 25 UK Startups to Watch
24 Oct 2023
Genomics plc has been selected from among more than 1,500 applications to be included in Bloomberg’s inaugural 25 UK Startups to Watch list. Bloomberg canvassed the UK to find 25 startups that represent the diversity and innovation of the country's startup scene. The Editors wanted to hear about companies that are growing fast, working on something truly unique and come from a diverse group of founders from all over the UK. Genomics plc co-Founder, Professor Sir Peter Donnelly, was also one of three founders from companies in the list to be on stage at the Bloomberg Technology Summit to discuss the Genomics plc story and the wider life sciences/tech sector.
Genomics plc bolsters executive leadership team with two new hires
25 Nov 2022
Genomics plc has today announced that Mark Toms and Nick DeFilippo have joined its leadership team as Chief Medical Officer and Chief Commercial Officer, respectively. Both join the company’s executive leadership team.
Genomics plc announces genetic risk scoring partnership with Our Future Health to test new personalised disease prevention approaches
10 Oct 2022
Genomics plc have today announced a partnership with Our Future Health to generate polygenic risk scores (PRS) as part of the research programme’s aim to find new ways to prevent, detect and treat common diseases such as dementia, diabetes, heart disease, stroke, and cancer.
Genomics plc announces extension of drug discovery collaboration with Vertex
3 Nov 2021
Companies confirm a two-year extension of their collaboration using genomics and machine learning to identify novel targets for innovative medicines and accelerate drug discovery
Genomics plc announces publication of article showing improved risk prediction for cardiovascular disease across ethnicities
6 Apr 2021
• Polygenic risk scores (PRS) substantially enhance risk prediction in cardiovascular disease (CVD), the #1 cause of death around the world
• These study results represent the first clinical validation of such a tool across multiple ancestries and ethnicities
Genomics plc’s integrated risk tool substantially improves coronary artery disease prediction
3 Mar 2021
• Genomics plc’s method outperforms current tools and could help save more than 2,000 lives annually in the US alone
• Opportunity to identify individuals who are at risk of heart disease and target immediate prevention